Table 3.
Correlation analysis for associations between mRNA expression, copy number variation (CNV) and protein expression of PSMD14 and clinicopathological features
| Primary dataset (TCGA) | Primary dataset (TCGA) | Secondary dataset (TMA) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| PSMD14 mRNA | PSMD14 CNV | PSMD14 protein | |||||||
| Low | High | p value | Low | High | p value | Low | High | p value | |
| Sex | |||||||||
| Female | 70 (24%) | 62 (28%) | 74 (29%) | 56 (22%) | 12 (24%) | 15 (23%) | |||
| Male | 218 (76%) | 160 (72%) | 0.354 | 178 (71%) | 196 (78%) | 0.067 | 39 (76%) | 49 (77%) | 0.991 |
| Age | |||||||||
| < 60 | 141 (49%) | 90 (41%) | 117 (46%) | 112 (44%) | 32 (63%) | 30 (47%) | |||
| ≥ 60 | 147 (51%) | 132 (59%) | 0.058 | 135 (54%) | 140 (56%) | 0.655 | 19 (37%) | 34 (53%) | 0.090 |
| T stage | |||||||||
| T1–2 | 120 (43%) | 62 (29%) | 100 (41%) | 80 (32%) | 38 (75%) | 45 (70%) | |||
| T3–4 | 159 (57%) | 154 (71%) | 0.001 | 143 (59%) | 167 (68%) | 0.044 | 13 (25%) | 19 (30%) | 0.618 |
| N stage | |||||||||
| N0 | 131 (48%) | 106 (50%) | 123 (51%) | 111 (46%) | 18 (35%) | 7 (11%) | |||
| N1–3 | 144 (52%) | 108 (50%) | 0.677 | 118 (49%) | 132 (54%) | 0.238 | 33 (65%) | 57 (89%) | 0.002 |
| Staging | |||||||||
| I–II | 74 (26%) | 40 (19%) | 62 (25%) | 50 (20%) | 14 (27%) | 4 (6%) | |||
| III–IV | 207 (74%) | 176 (81%) | 0.040 | 183 (75%) | 197 (80%) | 0.181 | 37 (73%) | 60 (94%) | 0.002 |
| HPVhr | |||||||||
| Negative | 223 (81%) | 190 (89%) | 205 (83%) | 207 (86%) | 40 (80%) | 48 (76%) | |||
| Positive | 53 (19%) | 23 (11%) | 0.011 | 41 (17%) | 35 (14%) | 0.502 | 10 (20%) | 15 (24%) | 0.628 |
| Smoker | |||||||||
| Never/ex | 187 (67%) | 136 (63%) | 173 (71%) | 147 (60%) | 27 (53%) | 24 (38%) | |||
| Active | 94 (33%) | 79 (37%) | 0.446 | 72 (29%) | 98 (40%) | 0.014 | 24 (47%) | 40 (63%) | 0.098 |
Analysis was performed using Fisher’s exact test or Chi-squared test. A p value below 0.05 was considered significant (bold)
HPVhr HPV high risk